Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    VolitionRx

    MCap

    USD76m

    Last close

    USD0.81

    ▲ 0.14 (20.90%)

    Canyon Resources

    MCap

    AUD262m

    Last close

    AUD0.19

    ▲ 0.02 (12.12%)

    Immix Biopharma

    MCap

    USD51m

    Last close

    USD1.82

    ▲ 0.12 (7.06%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Cantargia (OMX: CANTA)

Last close As at 20/11/2024

SEK1.83

▲ −0.02 (−1.08%)

Market capitalisation

SEK336m

Cantargia is a clinical-stage biotech company based in Sweden. It is developing two assets against IL1RAP, CAN04 and CAN10. CAN04 is being studied in several solid tumours with a main focus on non-small cell lung cancer (NSCLC) and pancreatic cancer. The most advanced trial is in Phase II.

Understanding of inflammation in cancer indicates that cytokines are produced not only by immune cells, but also by cancer cells to evade immune responses, making cytokines promising oncology targets. Further, recent Phase II data for AbbVie’s lutikizumab has increased interest in Cantargia’s CAN10, as it blocks IL-33 and IL-36 in addition to IL-1.

Latest Insights

View More

Healthcare | Flash note

Cantargia — Encouraging data for nadunolimab in CANFOUR

Healthcare | Flash note

Cantargia — First patient treated in Phase II part of TRIFOUR

Healthcare | Update

Cantargia — Next phase of clinical development in sight

Healthcare | Update

Cantargia — Strong momentum in first nine months of FY22
Visit Website

Sector

Healthcare

Equity Analyst

Arron Aatkar

Analyst

Key Management

  • Goran Forsberg

    CEO

Balance Sheet

Forecast net debt (SEKm)

N/A

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (38.6) (51.3) (52.2)
Relative (35.1) (49.5) (58.2)
52 week high/low SEK5.0/SEK1.8

Financials

Cantargia is developing antibodies against IL1RAP. Interim data from CANFOUR (Phase Ib/IIa) in NSCLC and PDAC suggest that nadunolimab could be synergistic with chemotherapy; the latest update (ESMO 2024) showed encouraging survival data in 40 NSCLC patients. Supportive clinical/biomarker data for PDAC have also been reported and Cantargia is preparing for a Phase IIb trial in PDAC. It shared positive data from TRIFOUR (Phase Ib portion), assessing nadunolimab in triple-negative breast cancer; the Phase II portion is ongoing with initial results expected in H125. A new Phase Ib/IIa clinical trial for nadunolimab in leukaemia is expected to start in Q424. A second programme, CAN10 (Phase I), is ongoing in autoimmune diseases. Following encouraging safety/biomarker data from the SAD cohort, the MAD part of CAN10 is now underway. At end-Q224, Cantargia had c SEK105m in cash and short-term investments.

Y/E Dec Revenue (SEKm) EBITDA (SEKm) PBT (SEKm) EPS (öre) P/E (x) P/CF (x)
2022A 0.0 (377.9) (371.8) (290.43) N/A N/A
2023A 0.0 (286.6) (280.0) (164.94) N/A N/A
2024E N/A N/A N/A N/A N/A N/A
2025E N/A N/A N/A N/A N/A N/A

Flash note

Healthcare

Cantargia — CAN04 progressing on all fronts

Update

Healthcare

Cantargia — Useful insights from CANOPY-1 data

edison tv

Healthcare

Cantargia – executive interview

edison tv

Healthcare

Cantargia: Edison Open House Healthcare 2022

Update

Healthcare

Cantargia — ‘Post-Novartis’ era has begun

edison tv

Healthcare

Cantargia – executive interview

Update

Healthcare

Cantargia — Sentiment affected, but fundamentals robust

edison tv

Healthcare

Cantargia – executive interview

Flash note

Healthcare

Cantargia — Novartis’s CANOPY-2 trial disappoints

edison tv

Healthcare

Cantargia – Edison Open House interview

Update

Healthcare

Cantargia — Buoyant on CANFOUR and CANOPY interims

Update

Healthcare

Cantargia — Great equity story underpins large share issue

edison tv

Healthcare

Executive interview – Cantargia

Update

Healthcare

Cantargia — Excellent end to the year

Update

Healthcare

Cantargia — CANFOUR study on track, US trial preparations

Update

Healthcare

Cantargia — Full Phase I data presented at ASCO

Update

Healthcare

Cantargia — Signs of growing interest in IL-1 pathway targets

edison tv

Healthcare

Executive interview – Cantargia

Update

Healthcare

Cantargia — Nidanilimab transitioning to Phase IIa

Update

Healthcare

Cantargia — CANFOUR interim Phase I presented at ESMO

Update

Healthcare

Cantargia — Phase IIa set to start in Q418

Initiation

Healthcare

Cantargia — Tackling tumour promoting inflammation